Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Ensem Therapeutics
Atavistik Bio, Inc
Ataturk University
Mayo Clinic
Kivu Bioscience Inc.
Alterome Therapeutics, Inc.
University College Cork
Bayer
Convalife (Shanghai) Co., Ltd.
Eastern Cooperative Oncology Group
Eli Lilly and Company
ViroMissile, Inc.
Arcus Biosciences, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Kaiser Permanente
AstraZeneca
Tizona Therapeutics, Inc
Normunity AccelCo, Inc.
Eli Lilly and Company
Institute of Cancer Research, United Kingdom
University of Colorado, Denver
MacroGenics
Institut Curie
SystImmune Inc.
University of Kansas Medical Center
Daiichi Sankyo
Eli Lilly and Company
Adela, Inc
Orano Med LLC
Radiopharm Theranostics, Ltd
Eli Lilly and Company
Ocellaris Pharma, Inc.
Medical College of Wisconsin
Fusion Pharmaceuticals Inc.
Innate Pharma
Brigham and Women's Hospital
OncoNano Medicine, Inc.
Ohio State University Comprehensive Cancer Center
Risen (Suzhou) Pharma Tech Co., Ltd.
Mayo Clinic
Tanabe Pharma America, Inc.
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Rondo Therapeutics
Actym Therapeutics, Inc.
New Mexico Cancer Research Alliance
LigaChem Biosciences, Inc.